1. Home
  2. URGN vs HFWA Comparison

URGN vs HFWA Comparison

Compare URGN & HFWA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • URGN
  • HFWA
  • Stock Information
  • Founded
  • URGN 2004
  • HFWA 1927
  • Country
  • URGN United States
  • HFWA United States
  • Employees
  • URGN N/A
  • HFWA N/A
  • Industry
  • URGN Biotechnology: Pharmaceutical Preparations
  • HFWA Banks
  • Sector
  • URGN Health Care
  • HFWA Finance
  • Exchange
  • URGN Nasdaq
  • HFWA Nasdaq
  • Market Cap
  • URGN 830.4M
  • HFWA 773.1M
  • IPO Year
  • URGN 2017
  • HFWA N/A
  • Fundamental
  • Price
  • URGN $20.62
  • HFWA $22.57
  • Analyst Decision
  • URGN Strong Buy
  • HFWA Buy
  • Analyst Count
  • URGN 8
  • HFWA 3
  • Target Price
  • URGN $28.50
  • HFWA $29.33
  • AVG Volume (30 Days)
  • URGN 921.6K
  • HFWA 153.1K
  • Earning Date
  • URGN 11-06-2025
  • HFWA 10-23-2025
  • Dividend Yield
  • URGN N/A
  • HFWA 4.25%
  • EPS Growth
  • URGN N/A
  • HFWA 53.03
  • EPS
  • URGN N/A
  • HFWA 1.65
  • Revenue
  • URGN $94,238,000.00
  • HFWA $232,877,000.00
  • Revenue This Year
  • URGN $36.41
  • HFWA $22.09
  • Revenue Next Year
  • URGN $118.04
  • HFWA $20.56
  • P/E Ratio
  • URGN N/A
  • HFWA $13.68
  • Revenue Growth
  • URGN 10.85
  • HFWA 14.16
  • 52 Week Low
  • URGN $3.42
  • HFWA $19.84
  • 52 Week High
  • URGN $21.71
  • HFWA $27.58
  • Technical
  • Relative Strength Index (RSI)
  • URGN 63.69
  • HFWA 42.41
  • Support Level
  • URGN $19.17
  • HFWA $22.44
  • Resistance Level
  • URGN $21.00
  • HFWA $23.53
  • Average True Range (ATR)
  • URGN 1.12
  • HFWA 0.64
  • MACD
  • URGN 0.35
  • HFWA -0.02
  • Stochastic Oscillator
  • URGN 83.19
  • HFWA 34.20

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About HFWA Heritage Financial Corporation

Heritage Financial Corp is a bank holding company. The company through its subsidiary provides commercial lending and deposit relationships with small businesses and their owners in its market areas and attracts deposits from the general public. It accepts various deposit products, such as noninterest demand accounts, money market accounts, savings accounts, and certificates of deposit. Besides, the Bank also makes real estate construction loans, land development loans, and consumer loans, and originates first mortgage loans on residential properties mainly located in its market area. Geographically, all the business activity functions through the region of the United States.

Share on Social Networks: